Immunovant, Inc. IMVT Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s operating lease right-of-use asset amortization?
- Immunovant, Inc. (IMVT) reported operating lease right-of-use asset amortization of $26K in Q1 2026.
- How has Immunovant, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Immunovant, Inc.'s operating lease right-of-use asset amortization increased by 18.2% year-over-year, from $22K to $26K.
- What is the long-term trend for Immunovant, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s operating lease right-of-use asset amortization has grown at a -45.3% compound annual growth rate (CAGR), from $1.11M to $99K.